Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q2 2024 · 10-Q
Revenue$3.95M$3.95M−0.3% vs Q2 2023 Net Income-$584.00K-$584.00KN/M vs Q2 2023 EPS Diluted$0.00$0.00N/M vs Q2 2023 Gross Profit$1,860,000+8.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Operating Cash Flowderived-$57,000N/M Free Cash Flowderived-$57,000— Margins · derivedGross margin47.0%+3.7 pt vs Q2 2023
Operating margin-14.7%+12.4 pt vs Q2 2023
Net margin-14.8%+17.7 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end